Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...

-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and ...

"Dosing the first patient in our Phase 1/2 trial of NEO-811 in renal cell carcinoma marks a pivotal inflection point for Neomorph, representing the first clinical evaluation of an asset from our ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical trials ...

Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). This is an ASCO Meeting Abstract from ...

Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range Invikafusp alfa ...

Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial). Previously presented at ESMO 2024, FPN: ...

Novo Nordisk (NVO) has released full data from a Phase 1b/2a trial for its novel obesity drug, amycretin noting that the injectable, designed to target GLP-1 and amylin receptors, caused up to 24% of ...

ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...